In this cohort study, use of MAUDs was associated with improved survival among patients with severe ALD. This finding highlights the need for improved access to MAUDs among patients with severe ALD.
Searching for Solutions
Findings provide implications for efforts aimed at discouraging vaping and suggest several possibilities for future work in the domain of narrative persuasion and social norm messaging.
These results support tightening alcohol use guidance in the United States, for both males and females, to no more than 1 drink per day.
NIH has cleared a first-in-human safety study of mitragynine, the primary alkaloid in kratom, to assess whether this opioid-receptor compound could be developed as a treatment for opioid use disorder. The move reflects both the promise seen in preclinical research and the central concern that kratom is itself psychoactive and potentially addictive, making safety and tolerability the immediate question.
The U.S. Drug Enforcement Administration opened a long-awaited administrative hearing June 29 on a proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, with proceedings expected to run into mid-July. A shift to Schedule III would formally recognize accepted medical use and ease research restrictions. AAPP supports the rescheduling of cannabis to enable the necessary research.
No summary available
Learn how wearable technology can enhance well-being, including prevention, treatment, and recovery for mental health and substance use.
The FDA has approved for eligible adults with early Alzheimer Disease to start lecanemab using weekly subcutaneous autoinjectors at home. The starting does is 500 mg weekly followed by 360 mg once weekly as maintenance.
A combination of THC and CBD eased symptoms in an especially frail population: patients with advanced dementia near the end of their lives.
Half as many young adults are misusing Adderall, Ritalin and other ADHD medications these days to help them remain alert at study or work, a new evidence review says. Misuse of ADHD stimulant meds among adults under 30 fell from 7.5% in 2016 to 3.7% in 2023, researchers report in the Journal of Clinical Psychopharmacology.
A new Primary Care Investment Guide from the Harvard Medical School Center for Primary Care outlines evidence-based strategies for strengthening advanced primary care while improving outcomes and lowering costs. Developed with support from the California Health Care Foundation and the Commonwealth Fund, the guide identifies integrated clinical pharmacy services as a key investment alongside behavioral health, care management and population health.
No summary available
No summary available
No summary available
AAPP and its pharmacy partners urged federal officials to take actions to restore public confidence in the vaccine advisory process. Our joint letter expresses concerns about ACIP's new charter, recommends key reforms, and emphasizes the critical role of the pharmacy workforce in protecting communities from vaccine-preventable diseases.
No summary available
Read the report that recaps 2026 State Legislative Sessions.
No summary available
This report describes the total number of clients receiving mental health and support services in 2024 including demographic characteristics, mental health diagnoses, and select National Outcome Measures (NOMs) for children and adults.
The study examined the general public’s perspectives towards SCS client considerations, community impacts, and health system impacts.
This paper reviews the evidence for injury to the hippocampus associated with opioid use and OUD.
This paper describes the phenomenon of compulsive tanning and its similarities to SUDs.
Findings suggest AI-based preliminary interpretation of urine drug testing results is fast and accurate and may provide substantial efficiency gains to the clinical service.
Increasing geographic availability of medications for opioid use disorder is likely a necessary but not sufficient strategy for addressing variation in access to care.
This trial did not find evidence that the STOP intervention for reducing risky opioid use produced greater reductions over 6 months compared with enhanced usual care.